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Abstract
Background: Hepatic artery lymph node (HALN) metastasis in pancreatic adenocarcinoma reportedly
confers a survival disadvantage. This has led some authors to propose it as an indicator against
pancreaticoduodenectomy (PD).
Methods: Consecutive patients who underwent PD during 2002–2012 were identified from the Univer-
sity of Louisville prospective hepatopancreaticobiliary database. Overall survival (OS) and disease-free
survival (DFS) were estimated using Kaplan–Meier analysis. The log-rank test and multivariate Cox
proportional hazards regression were used in further analyses.
Results: A total of 420 patients underwent PD during the period of study, of whom 197 had lymph node
(LN) metastasis. Among these, 41 (20.8%) patients had disease-positive HALNs. The HALN was the only
site of LN metastasis in only three of the 247 patients (1.2%). Median follow-up was 18.5 months
(interquartile range: 4.1–28.2 months). Median OS and DFS were 22.7 months [95% confidence interval
(CI) 19.0–26.3] and 12.6 months (95% CI 10.2–15.2). There was no significant difference in median OS
between HALN-positive patients (18.4 months, 95% CI 12.3–24.0) and HALN-negative patients (19.7
months, 95% CI 16.7–22.6) (P = 0.659). On multivariate analysis, the hazard ratio (HR) of death was
highest among patients with an LN ratio of >0.2 (HR 1.2, 95% CI 1.1–1.29; P = 0.012) followed by those
with poorly differentiated histology (HR 1.09, 95% CI 1.04–1.11; P = 0.029).
Conclusions: In pancreatic adenocarcinoma patients with LN disease, survival after PD is comparable
regardless of HALN status. Therefore, HALN-positive disease should not preclude the performance of PD.
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Introduction
Operative resection and adjuvant chemotherapy remain the only
effective course of therapy for pancreatic cancer although actual
5-year survival rates after successful resection and optimal
medical treatment are only 12–18%.1 Even with improvements in
perioperative care, pancreaticoduodenectomy (PD) is associated
with morbidity and mortality rates of 24% and 2%, respectively.
The ability to identify a subset of patients in whom surgery does
not confer a survival advantage would spare these patients the
morbidity of a non-therapeutic procedure. Various authors have
sought to identify clinicopathological prognostic markers in pan-
creatic cancer. The most important prognostic factors in patients
who have undergone surgery with curative intent for pancreatic
head adenocarcinoma are the presence of regional lymph node
(LN) metastases and the LN ratio.2–4
Resection of the hepatic artery LN (HALN) or LN8a [Japan
Pancreas Society (JPS) staging] is often performed routinely
during PD.5 This LN is located along the common hepatic artery
near the take-off of the gastroduodenal artery (GDA). Removal of
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this LN not only gives better access to and visualization of the
GDA, but also facilitates the location of a suprapancreatic portal
vein. In patients with pancreatic head malignancy, according to
the JPS classification, the HALN is a second-echelon LN. In a
study by Kayahara et al., metastatic disease to the 8a LN (HALN)
occurred in 9.7% of patients.6 Several studies have reported a
significantly worse prognosis in patients with HALN metastasis.7–9
There have been reports that involvement of the HALN represents
a survival disadvantage similar to that implied by liver metastases
or peritoneal disease in patients with pancreatic head cancers.8 In
light of these data, some centres perform routine frozen-section
analysis of this node and will not perform a PD if this node is
positive for metastasis. However, there is still uncertainty about
the prognostic significance of metastasis to the HALN. The aim of
this study was to assess the prognostic relevance of the HALN and
to assess whether its status should be used as a criterion for sur-
gical selection.
Materials and methods
A review of the single-institution prospective patient
hepatopancreatobiliary database at the University of Louisville
was performed. Consecutive patients who underwent PD for pan-
creatic adenocarcinoma during 2002–2012 were included in this
study. Patients were excluded if the data available for them were
incomplete, if final pathology showed non-pancreatic adenocar-
cinoma and if they were aged <18 years. Institutional review board
approval was obtained.
A disease-positive LN was defined by the presence of metastasis
on routine haematoxylin and eosin staining. A positive resection
margin was defined by the finding of tumour cells within ≤1 mm
of the final resection margin. The patient’s LN ratio was defined
according to the total number of positive LNs divided by the
total number of LNs harvested. The HALN or LN8a was required
to have been clearly identified intraoperatively by the primary
surgeon and sent as a separate specimen for pathological
investigation.
Patients were divided into four distinct subsets based on the
presence of metastases to the HALN or peripancreatic LNs
(PPLNs). These four groups represented patients who were,
respectively: (i) LN disease-negative (HALN–/PPLN–); (ii)
HALN+/PPLN–; (iii) HALN+/PPLN+, and (iv) HALN–/PPLN+.
Overall survival (OS) and disease-free survival (DFS) were
defined as survival in months from the date of surgery. Overall
survival was calculated from surgery until the date of the last
follow-up or death. Similarly, DFS was calculated from the date of
surgery to the date of the first recurrence or the last recurrence-
free follow-up. Statistical analysis was performed using IBM®
SPSS® Statistics for Windows Version 21 (IBM Corp., Armonk, NY,
USA). Categorical variables were analysed using the chi-squared
and Fisher’s exact tests; numeric variables were analysed using
the independent-samples t-test. Kaplan–Meier curves were con-
structed and the log-rank test was used to evaluate significant
differences among clinical and pathological variables. Variables
that achieved a P-value of <0.2 were entered into a Cox
proportional hazards regression model for final multivariate
analysis. A P-value of ≤0.05 was considered to indicate statistical
significance.
Results
During the study period, 420 patients underwent PD for pancre-
atic adenocarcinoma. Data on the intraoperative identification
and separate pathological evaluation of the HALN were available
for 247 (58.8%) of these patients. Of the 247 patients, LN metas-
tasis was seen in 197 (79.8%) patients; the remaining 50 (20.2%)
patients had no evidence of LN disease. In three (1.2%) patients
the HALN was the only site of metastasis. The median number of
LNs examined per specimen was 22 [interquartile range (IQR):
15–27]. The median number of positive LNs was 4.0 (IQR: 1.0–
5.5) and the median size of LN metastases was 11 mm (IQR:
5.5–18.0 mm). A total of 38 patients, representing 15.4% of the
total cohort and 19.3% of LN disease-positive patients demon-
strated positive findings in both the HALN and PPLNs (HALN+/
PPLN+). A total of 156 patients representing 63.2% of the
total cohort and 79.1% of LN disease-positive patients showed
positive findings for metastasis in PPLNs but not in the HALN
(HALN−/PPLN+).
Table 1 shows a comparison of the two groups represented by
HALN+ and HALN− patients. These groups were comparable
except that the HALN+/PPLN+ group had a significantly higher
number of disease-positive LNs, higher LN ratio and greater
lymphovascular invasion (LVI).
The median follow-up for this study was 18.5 months (IQR:
4.1–28.2 months). Survival analysis showed that median OS in the
entire cohort was 22.7 months (IQR: 11.8–40.4 months, 95% CI
19.0–26.3). A total of 32 patients were lost from follow-up and 114
patients died over the follow-up period. Patients with LN disease
had a median OS of 19.5 months (IQR: 11.0–33.0 months, 95% CI
15.4–23.6). Lymph node disease-negative patients had a better
median survival of 40.2 months (IQR: 26.1–63.0 months, 95% CI
29.2–76.2); this difference was statistically significant (P < 0.001).
Among patients with node-positive disease (Fig. 1), the HALN+/
PPLN+ group had a median OS of 16.9 months (IQR: 10.0–26.0
months, 95% CI 11.7–25.9), whereas the HALN−/PPLN+ group
had a median OS of 20.5 months (IQR: 11.8–33.0 months, 95% CI
16.0–24.0) (P = 0.659).
Median DFS in the entire cohort was 12.6 months (IQR: 7.4–
33.8 months, 95% CI 10.2–15.2). Patients with disease-positive
LNs had a lower median DFS of 10.8 months (IQR: 8.4–13.3
months, 95% CI 6.9–15.3) (P < 0.001). Among patients with
disease-positive LNs (Fig. 1), the HALN+/PPLN+ group had a
median DFS of 10.6 months (IQR: 8.3–12.7 months, 95% CI
8.4–12.6) which was comparable with that in the HALN−/PPLN+
group (median DFS: 11.6 months, IQR: 6.3–16.8 months, 95% CI
7.9–15.0) (P = 0.219).
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Univariate and multivariate survival analyses of patients with
LN-positive disease are shown in Table 2. Margin status,
perineural or lymphovascular invasion, T-stage and adjuvant
chemotherapy had no effect on survival. An LN ratio of >0.2 (P =
0.001), poorly differentiated histology (P = 0.043) and vascular
invasion (P = 0.026) were associated with significantly shorter
OS on univariate analysis. These variables along with LVI (P =
0.196) were then entered into a multivariate Cox proportional
hazards model. On multivariate analysis (Table 2), only LN ratio
[hazard ratio (HR) 1.13, 95% CI 1.00–1.23; P = 0.012] and poorly
Table 1 Clinicopathologic variables of patients with lymph node metastases: comparison of patients with (HALN+) and without (HALN−)
hepatic artery lymph node (HALN) metastatic disease
HALN– (n = 156) HALN+ (n = 41) P-value
Lymph nodes retrieved, median (range) 21 (5–58) 20 (5–41) 0.290
Lymph nodes positive, median (range) 3 (1–24) 6 (1–22) 0.012
Lymph node ratio, median (range) 0.14 (0.02–0.90) 0.20 (0.30–0.57 0.001
Size of metastasis, mm, median (range) 11 (2–26) 13 (3–25) NA
Tumour stage, n (%) T1 3 (2.4%) 0 0.528
T2 7 (5.7%) 3 (9.1%)
T3 113 (91.9%) 30 (90.9%)
Differentiation, n (%) Good 11 (7.4%) 3 (7.3%) 0.470
Moderate 71 (47.7%) 17 (41.5%)
Poor 21 (14.1%) 10 (24.4%)
Perineural invasion, n (%) 85 (77.3%) 27 (87.1%) 0.317
Lymphovascular invasion, n (%) 62 (57.4%) 26 (81.3%) 0.021a
Vascular invasion, n (%) 10 (6.7%) 5 (12.2%) 0.323
Positive margin, n (%) 21 (14.1%) 8 (19.5%) 0.462
Adjuvant chemotherapy, n (%) 56 (60.8%) 17 (56.6%) 0.160
aSignificant at P ≤ 0.05.
NA, not applicable.
Figure 1 Kaplan–Meier curves for survival in patients (n = 197) with node-positive disease for (a) overall survival (OS) and (b) disease-free
survival (DFS). HALN, hepatic artery lymph node; PPLN, peripancreatic lymph node(s); 95% CI, 95% confidence interval; IQR, interquartile
range
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differentiated histology (HR 1.09, 95% CI 1.02–1.30; P = 0.029)
were significant predictors of worse OS.
Similar results were found in an analysis of DFS: an LN ratio of
>0.2 (P = 0.002) and a positive resection margin (P = 0.044) were
associated with shorter DFS on univariate analysis. These vari-
ables along with poorly differentiated histology (P = 0.072) were
then entered into a multivariate Cox proportional hazards model.
On multivariate analysis only, LN ratio (HR 2.3, 95% CI 1.2–4.3;
P = 0.013) was a significant predictor of shorter DFS.
Discussion
The presence of nodal metastases has been shown to be an inde-
pendent prognostic factor in pancreatic adenocarcinoma.3,4,7
Unfortunately, as with most other independent prognostic
markers in resectable disease, this can only be assessed at the time
of surgery. Accurately identifying those patients in whom PD
would be futile in terms of their subsequent survival would be
advantageous. The HALN is an anatomically constant, easily
accessible node, which is routinely harvested at a revocable point
during PD. Therefore, there has been significant interest in evalu-
ating this node as a potential intraoperative prognostic marker.
Previous studies demonstrate that metastasis to the HALN
occurs in 9.7–24.0% of patients.6,7 The current study found a rate
of 16.6%, which was in concordance with those reported previ-
ously. The location of pancreatic node-positive disease has been
shown to be a significant prognostic marker for survival: patients
with metastases to the superior mesenteric artery and anterior
pancreatic nodes fare poorly compared with those with
peripancreatic nodal metastasis.10 However, another study
reported no survival difference between patients with first- and
second-echelon LN disease.11
Subsequently, a study by Maithel et al.8 evaluated 49 patients
with HALN metastasis and found a significant reduction in
survival, similar to that in patients with carcinomatosis or
liver metastases. Cordera et al.9 evaluated 55 patients of whom 10
had HALN metastases; these 10 patients had poorer OS and no
longterm survival. Similar results were seen in two other
studies, which showed that HALN disease conferred a survival
disadvantage.7,12
At the study institution, the HALN is routinely harvested
during PD by most surgeons and is separately examined by his-
topathology. As expected, a majority (79.8%) of the patients in the
present series were found to have LN metastasis, which is in line
with the ranges described in previous reports. Isolated HALN
metastasis in this study was extremely rare (1.2%), which is con-
sistent with prior studies and lends credence to the supposition
that the HALN is unlikely to represent a first-echelon node for
metastasis.6 Among the patients with node-positive disease, 79.3%
did not have HALN metastasis and only 19.3% had HALN metas-
tasis in the presence of PPLN metastasis. As various studies have
clearly established that LN metastasis is associated with worse OS,
the present study concentrated on only patients with node-
positive disease.3,4,7 As Table 1 shows, patients in the HALN+/
PPLN+ group had a significantly higher rate of nodal metastasis
with respect to number of positive LNs, as well as the LN ratio.
The median OS of 23 months in the whole cohort is compa-
rable with rates reported in the current literature. Patients with
node-negative disease did significantly better. Although OS was
reduced in patients with HALN metastases, the difference in OS
between these and other patients with node-positive disease was
not statistically significant. Based on the results of the current
study, the present authors do not agree that HALN status should
be used as a criterion for selection for PD. This conclusion differs
from those of some previous studies. The current study is distinct
in its large number of HALN+ patients (n = 41; numbers in
previous studies range from 10 to 237–9) and lengthy follow-up
period. Some of the prior studies included a mix of histologies,7,8
Table 2 Factors affecting survival
Variable Patients, n (%) Univariate analysis Multivariate analysis
P-value Hazard function 95.0% CI P-value
HALN + 41 (20.8%) 0.659
LN ratio >0.2 82 (41.6%) 0.001a 1.129 1.0–1.2 0.012b
Well differentiated 14 (10.5%) 0.043a 0.680 0.34–1.1 0.077
Moderately differentiated 88 (66.2%) Reference group
Poorly differentiated 31 (23.3%) 1.090 1.02–1.33 0.029b




Perineural invasion 112 (79.4%) 0.800
Lymphovascular invasion 88 (62.8%) 0.200
aSignificant on univariate analysis (P ≤ 0.05).
bSignificant on multivariate analysis (P ≤ 0.05).
95% CI, 95% confidence interval; HALN, hepatic artery lymph node; LN, lymph node.
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which makes the interpretation of survival analyses difficult. In
the one comparable study with an exclusively adenocarcinoma-
associated histology, patient numbers were low (HALN+ disease
in 10 of 55 patients) and showed a trend towards worse OS.9 The
study by LaFemina et al.12 included fewer patients with HALN+
disease than this study (23 of 147 patients), looked at only pan-
creatic adenocarcinomas and found significantly worse OS and
DFS in these patients. In the current study, OS in HALN+ patients
was 16.9 months, which is higher than OS reported at the
Memorial Sloan–Kettering and Fox Chase Cancer Centers.9,12
Previous studies have used the LN ratio as a surrogate for a
greater burden of LN disease (LN ratio of >0.2) and have shown
poorer prognoses in patients with higher ratios.13–15 The current
study confirmed the LN ratio as an independent prognostic pre-
dictor of poorer OS, as was a poorly differentiated histology. This
study also validates the role of poorly differentiated histology as an
independent prognostic marker for a poor prognosis with regard
to OS, a finding similar to those reported in the literature.4
In the current study, patients with HALN metastases had a
significantly higher tumour burden. Therefore, the authors believe
that HALN disease should be used as a surrogate not only for a
higher tumour burden, but also for a worse tumour biology.
However, larger studies are required to further define the signifi-
cance of disease in this node. The suggested role for HALN metas-
tasis (or positive nodal disease) may refer to its preoperative
evaluation with endoscopic ultrasound or laparoscopic staging.
As this node is positive in 10–24% of patients (16.6% in this
study), a subset of patients with a higher disease burden and poor
tumour biology can be identified and selected for neoadjuvant
chemotherapy.
There are some limitations to this study. Data on HALN status
were unavailable for a significant portion of patients submitted to
PD (173 of 420 patients). This primarily represents a practice
preference of some surgeons at this institution; however, the
exclusion of these patients may have contributed to some degree
of selection bias. In addition, this study included a larger propor-
tion of node-positive patients (79.8%) compared with other
reports in the literature.
Conclusions
The HALN is almost never the isolated site of disease. Metastasis
in the HALN is associated with a higher burden of LN metastasis.
However, among patients with node-positive pancreatic head
adenocarcinoma, the presence of HALN-positive disease is not an
independent adverse prognostic marker for OS and therefore
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